Prior to the IPO, Unity raised a total of $290.6 million in seven funding rounds. Investors include Hercules Capital, Invus and Arch Venture Partners. In 2020, the company performed less than exceptionally in its first major study, laying off some employees and seeing a decline in its stock market valuation. In addition to senescence, the company currently focuses on ophthalmology and neurology. Founded in 2016, the clinical-stage biopharmaceutical company raised a total of $225 million in its Series A funding round in the same year. The two investors were Versant Ventures and Bayer Pharmaceuticals, the latter of which acquired BlueRock in August 2019. The acquisition (which had an enterprise value of $1 billion in upfront and milestone payments) strengthens the company`s initiatives in merging genetic engineering and therapeutics for applications in neurology, immunology, ophthalmology and cardiology. Jeff Bezos, the richest man in the world, also owns Blue Origin, which successfully flew him into suborbital space in July 2021. Co-founder Yuri Milner is a theoretical physicist and arguably Russia`s most influential venture capitalist.
Milner funded and created the Breakthrough Prize (a series of international science prizes that award $3 million, the world`s largest prize to annual winners). Led by Dr. Anirvan Ghosh as CEO, Dr. Judith Campisi and Dr. Nathaniel David are among the founders of the company. Dr. Campisi is a prominent biogerontologist known for her research on cellular senescence. As President, Dr. David is a scientific entrepreneur with a PhD in Molecular and Cellular Biology from UC Berkeley.
Prior to joining Unity, Dr. Ghosh served as Executive Vice President at Biogen and led the company`s early-stage research and development group. He was also Global Head of Neuroscience and Biomarker Discovery at Swiss healthcare giant Roche. In a 2009 tax return, the company reported assets of over $25 million and generated over $18 million in revenue that year with over $18 million in revenue. [5] From innovative physicians and health practitioners specializing in preventive medicine to scientists, researchers, laboratory technicians, naturopaths, nutritionists, nurses and wellness specialists, our team is committed to supporting you. We know it`s hard to go it alone, and that`s why we`re here to help you find your path to health, well-being and vitality throughout life. BioSplice was founded in 2008 by Turkish-American billionaire Osman Kibar. Kibar holds a PhD in biophotonics and invented a cancer diagnostic system that was eventually acquired (as an emerging Genoptix company) for $476 million by Swiss pharmaceutical giant Novartis in 2011.
Based in Boston, Life Biosciences develops new drugs and therapies that prevent, treat or reverse several age-related diseases. To do this, the company studies the mechanisms of aging and holds exclusive licenses with top research institutions and academics for at least three of the eight known factors underlying the senescence process. The ultimate goal is to tackle aging itself therapeutically and extend human lifespan. These experiments, conducted largely by Elevian`s scientific founders in Harvard`s Department of Stem Cells and Regenerative Biology, allowed the company to identify its lead drug candidate: recombinant human GDF11. In preclinical models, GDF11 is already showing its effectiveness in regenerating the heart, brain, muscles and other tissues damaged by age-related diseases such as stroke and diabetes. The biotech startup holds exclusive worldwide rights to Harvard University`s patent portfolio for GDF11. Currently, Insilico`s in-house research focuses on the treatment of cancer, fibrosis, Alzheimer`s disease and aging. In early 2021, Insilico successfully demonstrated the transformative value of its AI solutions by discovering, developing and testing a new drug for pulmonary fibrosis for less than $3 million in just 18 months.
A few months later, the company repeated its success in developing drugs for kidney fibrosis. In September 2021, Elevian raised $40 million from investors including Leslie Ventures, Bold Capital Partners and Prime Movers Lab. This fund is intended to finance phase 1 studies on stroke recovery. Since its inception in July 2017, the company has raised a total of $64.3 million from a dozen investors. Philip Smith oversees the research and development of every article that appears in Life Extension Magazine®. Mr. Smith has been editor of Life Extension magazine for® 16 years. His experience in national monthly magazines, graphic design and nutrition research as well as a hand-picked team of physicians, designers and editors help create an innovative and progressive magazine on life extension. Prior to Life Extension®, Mr.
Smith was editor-in-chief of GQ Magazine. As Alphabet`s health and longevity research subsidiary, Calico enjoys the enormous social and financial clout of the 5th most valuable company (only about $1.54 trillion) in the world. Futurists > companies that > shape the future The 11 Best Longevity Companies That Lead in the Search for Life Extension The human quest to stay young and live forever has long since left the realm of fantasy to shake up finance with a series of life-affirming shocks. Fueled in part by myths like the fountain of youth and vampiric regeneration, ambitious startups in Silicon Valley, biotech, and the pharmaceutical industry have developed different roadmaps that could soon lead us to extended youth, extended lifespan, and immortality. Formerly known as Samumed, BioSplice Therapeutics focuses on developing the science and techniques of tissue regeneration to treat cancer, osteoarthritis and other age-related diseases. As the new name suggests, the company`s stated mission is to restore human health through innovative therapies that use alternative splicing. To date, the company has raised $778 million in five funding rounds and 11 investors, including Sands Capital, Verition Fund Management, Ali Sabancı and Ergun Öze. As a life sciences company focused on the healthcare market, Juvenescence develops prescription drugs and consumer products for age management, disease prevention and improved metabolic efficiency. As a pioneer in cell and tissue regeneration, the company is also using AI, machine learning and data to accelerate the development and drive efficacy of new drugs. Life Extension — which is privately owned by William Faloon and Saul Kent and employs about 315 people — started exclusively in the business-to-consumer (B2C) space, Gilner says. To date, Human Longevity has raised a total of $330 million following a Series C funding round in 2019 involving Emerging Technology Partners and Celgene. The company managed to reach a post-silver valuation of $1 billion to $10 billion in the same year, although it has already suffered numerous setbacks, including the departure and subsequent lawsuit against founder Craig Venter, which was later dismissed.
In July 2021, BlueRock announced that the U.S. FDA had granted accelerated approval for DA01 for advanced Parkinson`s disease. DA01 is the company`s “pluripotent stem cell-based dopaminergic neuronal therapy” being evaluated in a Phase 1 study. Human Longevity Inc. was founded in 2013 by author and entrepreneur Peter Diamandis and genomics pioneer Craig Venter. The company aims to create the world`s most comprehensive database of human phenotypes and genotypes, and then use advanced AI, machine learning and genomic sequence analysis to develop new methods and therapies to treat age-related diseases, reverse the aging process, and enable people to live full, better lives. PayPal`s Peter Thiel and Amazon`s Jeff Bezos are two of the big names that backed Unity Biotechnology even before its IPO in May 2018. The company, which is now listed on the Nasdaq stock exchange, was founded in 2009 to develop advanced therapies and transformative drugs to treat age-related diseases, with a focus on aging cells. Our advisory board comes from all disciplines and regions of the world. What they have in common is their belief in making a healthier, longer life a reality for all.
At least two famous billionaires (both middle-aged) have bet on Altos Labs to extend the good times a little more. Founded in September 2021 by Amazon CEO Jeff Bezos and Russian-Israeli entrepreneur Yuri Milner, Altos Labs aims to use cellular reprogramming technology to develop life-extending therapies for humans.
